Home  »  Business   »  After A -79.69% Fall This Year Is Atara Biotherape...

After A -79.69% Fall This Year Is Atara Biotherapeutics Inc. (NASDAQ:ATRA) A Better Buy Than Others?

In last trading session, Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw 1.43 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $3.41 trading at -$0.18 or -5.01% at ring of the bell on the day assigns it a market valuation of $374.35M. That closing price of ATRA’s stock is at a discount of -487.68% from its 52-week high price of $20.04 and is indicating a premium of 17.01% from its 52-week low price of $2.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.12 million shares which gives us an average trading volume of 2.64 million if we extend that period to 3-months.

For Atara Biotherapeutics Inc. (ATRA), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 10 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.76 in the current quarter.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Atara Biotherapeutics Inc. (NASDAQ:ATRA) trade information

Upright in the red during last session for losing -5.01%, in the last five days ATRA remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $3.41 price level, adding 26.19% to its value on the day. Atara Biotherapeutics Inc.’s shares saw a change of -78.36% in year-to-date performance and have moved -27.45% in past 5-day. Atara Biotherapeutics Inc. (NASDAQ:ATRA) showed a performance of -19.39% in past 30-days. Number of shares sold short was 8.04 million shares which calculate 3.35 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $18.79 to the stock, which implies a rise of 81.85% to its current value. Analysts have been projecting $3.00 as a low price target for the stock while placing it at a high target of $50.00. It follows that stock’s current price would drop -1366.28% in reaching the projected high whereas dropping to the targeted low would mean a gain of 12.02% for stock’s current value.

Atara Biotherapeutics Inc. (ATRA) estimates and forecasts

Statistics highlight that Atara Biotherapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -63.33% of value to its shares in past 6 months, showing an annual growth rate of 48.21% while that of industry is 1.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 15.60% in the current quarter and calculating 34.40% increase in the next quarter. This year revenue growth is estimated to rise 293.90% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $5.27 million for the same. And 8 analysts are in estimates of company making revenue of $20.82 million in the next quarter that will end on Dec 2022. Company posted $3.92 million and $7.55 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 34.40% while estimating it to be 175.80% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.70% during past 5 years.

ATRA Dividends

Atara Biotherapeutics Inc. is more likely to be releasing its next quarterly report between February 28 and March 04 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s Major holders

Insiders are in possession of 0.72% of company’s total shares while institution are holding 106.49 percent of that, with stock having share float percentage of 107.26%. Investors also watch the number of corporate investors in a company very closely, which is 106.49% institutions for Atara Biotherapeutics Inc. that are currently holding shares of the company. JP Morgan Chase & Company is the top institutional holder at ATRA for having 8.19 million shares of worth $76.08 million. And as of Mar 30, 2022, it was holding 8.77% of the company’s outstanding shares.

The second largest institutional holder is Baupost Group, Inc,.(The) LLC, which was holding about 8.12 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 8.70% of outstanding shares, having a total worth of $75.47 million.

On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 4.18 million shares of worth $32.55 million or 4.47% of the total outstanding shares. The later fund manager was in possession of 2.5 million shares on Mar 30, 2022, making its stake of worth around $23.24 million in the company or a holder of 2.68% of company’s stock.

Leave a Comment

Your email address will not be published.

On Key

Related Posts